华仁药业 reported revenue of ¥0.61B for the period ended 2026-06-30, -3.0% year on year. Net income was ¥0.03B, a 5.0% net margin on a 32.6% gross margin. The largest revenue line is 基础输液 at 36% of the total. Free cash flow for the period was ¥0.06B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.61B | -3.0% |
| Gross profit | ¥0.20B | — |
| Operating income | ¥0.04B | — |
| Net income | ¥0.03B | -22.4% |
| Gross margin | 32.6% | Net margin 5.0% |
| Revenue Q/Q | -4.8% | — |
| Segment | Revenue | Share |
|---|---|---|
| 基础输液 | ¥0.22B | 36.4% |
| 腹透液 | ¥0.21B | 34.4% |
| 治疗制剂 | ¥0.10B | 17.2% |
| 医疗器械 | ¥0.06B | 10.4% |
| 其他 | ¥0.01B | 1.6% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.41B | 67.4% |
| R&D | ¥0.03B | 5.0% |
| SG&A | ¥0.09B | 15.5% |
| Tax & other | ¥0.01B | 1.5% |
| Item | Amount |
|---|---|
| Total assets | ¥2.75B |
| Total liabilities | ¥1.81B |
| Shareholders' equity | ¥0.94B |
| Equity / assets | 34.2% |
| Operating cash flow | ¥0.06B |
| Capital expenditure | ¥0.00B |
| Free cash flow | ¥0.06B |
| Cash conversion (OCF / net income) | 247% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
向日葵 ・ 万讯自控 ・ 顺网科技 ・ 长盈精密 ・ 东方日升 ・ 瑞普生物 ・ 经纬辉开 ・ 阳谷华泰 ・ ST亚光 ・ 聆达股份 ・ 锐奇股份 ・ 银河磁体
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies